Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07035964 · ClinicalTrials.gov registry record · NA
Effects of Effera Human Lactoferrin at One Dose Compared to Placebo on Gut Permeability
A NA study of Gut Health and Gut Permeability, sponsored by Helaina.
- Recruiting
- Registry status
- NA
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT07035964: Recruiting NA study of Gut Health and Gut Permeability, sponsored by Helaina.
NCT07035964 is a NA study of Gut Health and Gut Permeability that is actively recruiting participants, run by Helaina. The registered enrollment target is 46 participants, below the 57-participant average among 9 other Gut Health trials with a reported enrollment target (19% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07035964, a NA study of Gut Health and Gut Permeability, is actively recruiting participants, sponsored by Helaina.
- RECRUITING
- Registry status
- NA
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the impact of 28-day supplementation with effera human lactoferrin, compared to a placebo control product on indicators of gut barrier health in males and females
Primary Outcome
Change from baseline of lactulose to mannitol ratio
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT human lactoferrin
Study Locations (1)
Illinois
- Biofortis Inc - Addison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2025-06-04 |
| Est. Completion | 2025-08-30 |
| Phase | NA |
What NCT07035964 shows while recruiting
NCT07035964 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 57-participant average among 9 other Gut Health trials with a reported enrollment target (19% lower).
The record links to 2 conditions, with Gut Health appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07035964 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT07035964 about?
NCT07035964 is a clinical study titled "Effects of Effera Human Lactoferrin at One Dose Compared to Placebo on Gut Permeability". The purpose of this study is to evaluate the impact of 28-day supplementation with effera human lactoferrin, compared to a placebo control product on indicators of gut barrier health in males and females
What is the current status of trial NCT07035964?
This trial is currently recruiting. It is a NA study. The enrollment target is 46 participants. The study started on 2025-06-04. Estimated completion is 2025-08-30.
What conditions does trial NCT07035964 study?
This clinical trial studies the following conditions: Gut Health, Gut Permeability.
What interventions are being tested in trial NCT07035964?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), human lactoferrin (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07035964?
This trial is sponsored by Helaina, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07035964 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gut Health
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07035964's enrollment target sits among peer trials
46 6th of 9 higher than 4 of 9 other Gut Health trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gut Health trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of B. Adolescentis iVS-1 Probiotic on Gastrointestinal Outcomes
RECRUITING · NA
-
An 8-Week Study Evaluating Gut and Digestive Health After Use of a Dietary Supplement System
RECRUITING · NA
-
The Effect Cranberry-Based Products on the Female Microbiome
RECRUITING · NA
-
Impact of Weizmannia (Bacillus) Coagulans JBI-YZ6.3 on Gut Health and Fecal Microbiome Changes
RECRUITING · NA
-
A Study to Evaluate the Effects of a Butyrate-Polyphenol Formulation on Gut Health and Associated Symptoms
RECRUITING · NA
-
Cardiometabolic Benefits of Potatoes Mediated Along the Gut-Vessel Axis in Adults With Metabolic Syndrome
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI